Prestige Consumer Healthcare (PBH) Sales Grow As Lower Profit Puts Fair Value In Focus

Prestige Consumer Healthcare (PBH) just released second quarter and first half 2026 results, reporting higher sales and revenue alongside lower net income and earnings per share, a combination that may influence how investors view the stock.

The market reaction has been sharp. Prestige Consumer Healthcare's share price fell 16.8% in the last trading day and is down 27.6% year to date, while its 1 year total shareholder return declined 27.8%. This signals fading momentum as investors reassess the stock after weaker profitability.

Scan how Prestige Consumer Healthcare compares to a curated 42 high quality undervalued stocks in light of shifting profitability and sentiment.

Prestige Consumer Healthcare now trades well below analyst targets and an estimated fair value, yet the profit hit is fresh in investors' minds. Is this caution mispriced, or exactly what the current earnings picture warrants?

Most Popular Narrative: 35% Undervalued

Prestige Consumer Healthcare closed at $44.32, while the most followed narrative anchors fair value at $67.80. This frames the current selloff as a steep discount that investors are still testing against the latest earnings wobble.

The planned contribution of about $900 million of free cash flow over three years, supported by guidance of at least $270 million in fiscal 2027 alone, gives Prestige Consumer Healthcare room to reduce leverage and lower interest expense, which feeds directly into net income and EPS.

See why 2 investors see Prestige Consumer Healthcare as 35% undervalued.

Result: Fair Value of $67.80 (UNDERVALUED)

Still, the Clear Eyes supply uncertainty and roughly US$2b net debt load could easily overturn this Prestige Consumer Healthcare undervaluation story.

Find out about the key risks to this Prestige Consumer Healthcare narrative.

Next Steps

Mixed emotions around Prestige Consumer Healthcare are clear, with fresh risks and rewards both on the table. Consider moving quickly and weighing the trade off yourself by reviewing the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Prestige Consumer Healthcare?

Do not stop with one stock story. Use fresh idea lists to cross check your thesis, spot patterns and keep your watchlist stocked with stronger possibilities.

• Hunt for quality at a discount by scanning companies flagged as 42 high quality undervalued stocks that combine solid fundamentals with appealing entry prices.
• Prioritize resilience and sleep better at night by focusing on a 32 resilient stocks with low risk scores that screens for businesses with sturdier profiles.
• Get ahead of the crowd by reviewing a 21 high quality undiscovered gems that highlights under-followed companies with strong underlying numbers.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com